Ultragenyx Pharmaceutical (RARE) Receivables - Net (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Receivables - Net of $121.0 million for Q1 2026, up 22.42% year-over-year from $98.8 million in Q1 2025, and up 12000.0% quarter-over-quarter from $1.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Receivables - Net (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Receivables - Net for 14 consecutive years, with $121.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 22.42% year-over-year to $121.0 million; the TTM figure through Mar 2026 stood at $121.0 million (up 22.42% YoY), while the FY2025 annual figure was $158.0 million, up 29.51% from the prior year.
- Receivables - Net climbed to $121.0 million in Q1 2026 per RARE's latest filing, from $1.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $124.5 million in Q2 2025 and bottomed at $1.0 million in Q4 2025.
- Historically, Receivables - Net has averaged $74.7 million across 5 years, with a median of $79.3 million in 2023.
- Annual changes were most pronounced in 2023 — Receivables - Net soared 166.87% — and 2025, when it tumbled 99.18%.
- Ultragenyx Pharmaceutical's Receivables - Net stood at $27.5 million in 2022, then jumped by 166.87% to $73.4 million in 2023, then surged by 66.24% to $122.0 million in 2024, then sank by 99.18% to $1.0 million in 2025, then surged by 12000.0% to $121.0 million in 2026.
- Business Quant data shows RARE's Receivables - Net at $121.0 million in Q1 2026, $1.0 million in Q4 2025, and $112.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200.00 Mn |
| Jun 30, 2026 | 200.00 Mn |
| Mar 31, 2026 | 121.00 Mn |
| Mar 31, 2026 | 121.00 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 112.54 Mn |
| Sep 30, 2025 | 112.54 Mn |
| Jun 30, 2025 | 124.46 Mn |
| Jun 30, 2025 | 124.46 Mn |
| Mar 31, 2025 | 98.84 Mn |
| Mar 31, 2025 | 98.84 Mn |
| Dec 31, 2024 | 122.00 Mn |
| Dec 31, 2024 | 122.00 Mn |
| Sep 30, 2024 | 93.30 Mn |
| Sep 30, 2024 | 93.30 Mn |
| Jun 30, 2024 | 105.98 Mn |
| Jun 30, 2024 | 105.98 Mn |
| Mar 31, 2024 | 100.25 Mn |
| Mar 31, 2024 | 100.25 Mn |